Zacks: Brokerages Anticipate Steris PLC (STE) Will Post Quarterly Sales of $739.40 Million

Brokerages expect Steris PLC (NYSE:STE) to report sales of $739.40 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Steris’ earnings, with estimates ranging from $733.30 million to $749.50 million. Steris posted sales of $715.97 million during the same quarter last year, which suggests a positive year-over-year growth rate of 3.3%. The company is scheduled to report its next earnings report on Wednesday, May 8th.

On average, analysts expect that Steris will report full-year sales of $2.75 billion for the current fiscal year, with estimates ranging from $2.75 billion to $2.76 billion. For the next financial year, analysts expect that the company will post sales of $2.90 billion, with estimates ranging from $2.89 billion to $2.91 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Steris.

Steris (NYSE:STE) last announced its quarterly earnings data on Monday, February 11th. The medical equipment provider reported $1.26 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.26. The business had revenue of $696.24 million during the quarter, compared to the consensus estimate of $687.90 million. Steris had a net margin of 9.85% and a return on equity of 12.50%.



Several brokerages have issued reports on STE. Stephens reissued a “buy” rating and issued a $135.00 price objective on shares of Steris in a research note on Thursday, February 14th. JMP Securities reissued a “buy” rating and issued a $135.00 price objective on shares of Steris in a research note on Thursday, February 14th. Zacks Investment Research reissued a “buy” rating and issued a $132.00 price objective on shares of Steris in a research note on Friday, November 16th. Finally, Sidoti raised their price objective on shares of Steris from $155.00 to $157.00 and gave the stock a “buy” rating in a research note on Thursday, December 6th. Five research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus target price of $138.20.

In related news, VP John Adam Zangerle sold 1,750 shares of Steris stock in a transaction that occurred on Friday, January 11th. The shares were sold at an average price of $110.00, for a total transaction of $192,500.00. Following the transaction, the vice president now directly owns 32,546 shares of the company’s stock, valued at $3,580,060. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Michael B. Wood sold 3,609 shares of Steris stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $121.79, for a total transaction of $439,540.11. The disclosure for this sale can be found here. Insiders have sold 10,396 shares of company stock valued at $1,226,593 in the last ninety days. Insiders own 2.38% of the company’s stock.

A number of hedge funds have recently modified their holdings of STE. State Board of Administration of Florida Retirement System grew its holdings in Steris by 6.2% in the third quarter. State Board of Administration of Florida Retirement System now owns 79,670 shares of the medical equipment provider’s stock worth $9,114,000 after purchasing an additional 4,684 shares during the last quarter. US Bancorp DE grew its holdings in Steris by 6.1% in the third quarter. US Bancorp DE now owns 49,409 shares of the medical equipment provider’s stock worth $5,653,000 after purchasing an additional 2,859 shares during the last quarter. Commerce Bank purchased a new position in Steris in the third quarter worth $249,000. WINTON GROUP Ltd purchased a new position in Steris in the third quarter worth $970,000. Finally, Los Angeles Capital Management & Equity Research Inc. grew its holdings in Steris by 8.3% in the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 10,480 shares of the medical equipment provider’s stock worth $1,199,000 after purchasing an additional 800 shares during the last quarter. 87.10% of the stock is currently owned by institutional investors.

NYSE STE traded up $0.38 during trading on Tuesday, hitting $123.93. The stock had a trading volume of 100,722 shares, compared to its average volume of 400,809. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.56 and a quick ratio of 1.99. The company has a market cap of $10.34 billion, a P/E ratio of 29.86 and a beta of 1.07. Steris has a one year low of $89.67 and a one year high of $123.75.

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 21st. Stockholders of record on Wednesday, February 27th will be paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 1.10%. The ex-dividend date is Tuesday, February 26th. Steris’s dividend payout ratio is presently 32.77%.

About Steris

STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.

Read More: Benefits of owning preferred stock

Get a free copy of the Zacks research report on Steris (STE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Steris (NYSE:STE)

Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.